<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009317</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3139-III-01</org_study_id>
    <nct_id>NCT04009317</nct_id>
  </id_info>
  <brief_title>Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of TQ-B3139 versus crizotinib in subjects with
      ALK-positive NSCLC that have received one chemotherapy regimen and have not received ALK
      inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control rate (DCR)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Percentage of subjects achieving CR, PR, stable disease (SD) and Non-CR/Non-progressive disease (PD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>ALK-positive NSCLC</condition>
  <arm_group>
    <arm_group_label>TQ-B3139</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-B3139 tablet 600mg administered orally , twice daily in 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crizotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Crizotinib tablet 250mg administered orally, twice daily in 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3139</intervention_name>
    <description>a multi-target protein kinase inhibitor.</description>
    <arm_group_label>TQ-B3139</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>a multi-target protein kinase inhibitor.</description>
    <arm_group_label>Crizotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.18 and 75 years. 2. Eastern Cooperative Oncology Group (ECOG) performance status
             score of 0 to 1.

             3. Life expectancy ≥12 weeks. 4. Histologically or cytologically confirmed advanced or
             metastatic NSCLC with ALK-positive.

             5. Has not received ALK tyrosine kinase inhibitor (TKI). 6. Has received one
             chemotherapy regimen for stage IIIB-IV NSCLC. 7. At least one measurable lesion. 8.
             Adequate organ system function. 9. Understood and signed an informed consent form.

        Exclusion Criteria:

          -  1. Has diagnosed and/or treated additional malignancy within 5 years prior to
             randomization. Exceptions include cured cancer carcinoma in situ of the cervix,
             intramucosal carcinoma of gastrointestinal tract, breast and melanoma skin cancers and
             superficial bladder tumors.

             2. Hypersensitivity to TQ-B3139 or crizotinib. 3. Has received any cancer therapy
             within 4 weeks or 5 times of t1/2. 4. Has received any major surgery within 4 weeks.
             5. Has received any radiotherapy or minor surgery aimed to cure cancer within 2 weeks.

             6. Acute toxicity that is ≥ Grade 2 caused by previous cancer therapy. 7. Has active
             viral, bacterial and fungal infections within 2 weeks before the first dose.

             8. Has serious cardiovascular disease within 3 months before the first dose. 9. Has
             currently uncontrollable congestive heart failure. 10. Has continuous arrhythmia ≥
             Grade 2, uncontrollable atrial fibrillation or QTc interval &gt; 480ms.

             11. Has interstitial fibrosis or interstitial lung disease ≥ Grade 3. 12. Brain
             metastases with symptom. 13. HBsAg positive and HBV DNA positive (≥ULN);HCV antibody
             and HCV-RNA positive (≥ULN); HIV positive or ≥HIV ULN.

             14. Has multiple factors affecting oral medication. 15. Has received a strong CYP3A
             inhibitors within 7days before the first dose. 16. Has received a strong CYP3A
             inducers. 17. Breastfeeding or pregnant women.; Men unwilling to use adequate
             contraceptive measures during the study.

             18. According to the judgement of the researchers, there are other factors that
             subjects are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Zhang, Doctor</last_name>
    <phone>020-87343088</phone>
    <email>zhangli@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang, Doctor</last_name>
      <phone>020-87343088</phone>
      <email>zhangli@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Li Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

